Biohit Oyj - Changes board/management/auditors

NEW DIRECTOR APPOINTED TO BIOHIT'S DIAGNOSTICS BUSINESS

BIOHIT OYJ STOCK EXCHANGE RELEASE ON 22 JANUARY 2010 AT 3:30 PM                 

NEW DIRECTOR APPOINTED TO BIOHIT'S DIAGNOSTICS BUSINESS                         

Yrjö E K Wichmann, MSc. econ., (51), has been appointed Director of Biohit    
Oyj's diagnostic business segment as of 1st February 2010.                      

Prior to joining Biohit, Mr Wichmann has been working for CapMan, most recently 
as Funds Raising Director. He has almost 20 years experience from financing and 
investment banking, and he has held positions as both Chief Financial Officer
and Equity Capital Markets Director within the healthcare technology industry.
  

As Director of the diagnostics business, Mr Wichmann reports to the President &
CEO and is member of the Diagnostics Management Team of Biohit Oyj.             


Further information:                                                            
Osmo Suovaniemi, M.D., Ph.D., Professor                                         
President & CEO                                              
Tel: +358-9-773 861                                                             
Email: osmo.suovaniemi@biohit.com                                               

Distribution:                                                                   
NASDAQ OMX Helsinki Oy                                                          
Central storage facility (www.oam.fi)                                           
Press                                                                           
www.biohit.com                                                                  


About Biohit Oyj                                                                

Established in 1988, Biohit Oyj is a Finnish biotechnology company quoted on the
NASDAQ OMX Helsinki since 1999. It applies a determined and persistent          
innovation and patenting strategy in its operations                             
(www.biohit.com/Company/History, www.biohit.com/Diagnostics/Literature and      
brochures and www.google.com / search “Aggressive innovation and paetenting     
stratergy in Finland”)                                                          

In cooperation with scientific communities, Biohit produces new technology,     
products and services based on research results and innovations for the         
development of safe and cost-effective liquid handling in laboratories as well  
as the early diagnosis and prevention of gastrointestinal tract diseases        

Biohit is divided into liquid handling and diagnostics business units. Liquid   
handling products include electronic and mechanical pipettes and dispensers, and
disposable tips, as well as pipette maintenance and calibration services for use
by research institutions, healthcare and industrial laboratories.               

The diagnostics business comprises products and analysis systems for the early  
detection of gastrointestinal diseases, such as the blood-sample based          
GastroPanel and GastroView, for diagnosing diseases of the stomach and   
associated risks, quick tests for the diagnosis of lactose intolerance,         
Helicobacter pylori infection and ColonView for the early detection of faecal   
occult blood. The Acetium capsule, developed to eliminate carcinogenic          
acetaldehyde in the gastrointestinal tract, is part of the strategic R&D work of
the diagnostics business unit, whose main objective is the prevention of        
gastrointestinal diseases.                                                      

Biohit Group employs a staff of approximately 370 in 9 countries. The company is
headquartered in Finland and has subsidiaries in France, Germany, the UK,       
Russia, India, China, Japan and the USA. Biohit's products are sold by          
approximately 450 distributors in 70 countries.                                 

Biohit's share (BIOBV) is quoted on the NASDAQ OMX Helsinki Small               
cap/Healthcare. Read more at www.biohit.com